RE: Robo2meRob2u
You prove once again that you are lacking the basics (or perhaps just deficient.)
actually, i didn't need to call onc about this. here is what a highly thought of poster (by the cult of which you are a member) had to say in November 2000 about Reo production, long before Cobra entered the picture.
“Reovirus cultures are commercially available through a number of cGMP pharmaceutical labs. Quantities to support clinical testing can be quite easily and inexpensively (actually dirt cheaply). Because the technology is available 'off the shelf', it doesn't just make any sense to go to the trouble and expense to build another lab.
There are no compelling trade secrets, and no "magic black box" technology to protect. (I'm not taking anything away fron ONC, their research has been admirable, but by their own admission the discoveries have been serendipitous. REOLYSIN is founded much more on excellent scientific observation than on innovative technological creation.
That is not to say that productive capacity currently exists for full scale commercial volumes, but that aspect ( if and when it is required) would not likely entail any significant delay to a marketing thrust. Current labs, with relatively minor equipment scale-ups, could easily satisfy demand. Culture cell counts double at each cellular division. Harvesting of the culture volumes at that point is literally limited only by the necessity to maintain todays 'seed crop' at a volume large enough to grow the harvest for tomorrow. It may take 6 weeks to grow the first litre, but tomorrow that litre will grow to 2 litres, and the following day it is 4 liters, and the next day 8 litres etc., etc.. It all adds up really quick once the seed crop reaches a 'critical mass'. At this point, the cost differential from day to day is next to zip, except for the larger containers and environmental controls required to contain and support the crop.
By perhaps licencing specific labs to grow cultures for specific therapeutic end-use, and/or licencing clinics to purchase REOLYSIN for the same specfic therapeutic end-use, ONC could sidestep all the hassles of both manufacturing and marketing, collect the licence fees and royalties from REOLYSIN, and concentrate investigating on futher applications of the reovirus. “
Stockhouse Post 2467132
Interestingly, this highly thought of poster has been completely silent when it comes to discussing why the company spent millions to “complete the manufacturing process” AFTER they announced such “completion” in Feb 2003.
It has also been stated before the money started flowing for the manufacturing process that one liter of reo is enough to treat up to 1,000 clinical patients – given oncy’s extremely small & slow rate of trials & enrolments, one liter will be enough to last them for another 6 years, yet they have literally spent millions “perfecting” the process YEARS AFTER announcing its “COMPLETION”.
but perhaps understanding the above is too much to expect from you given your apparent "deficiency"
As for your other question, may I suggest reading some of my recent posts – oh yea, I forgot, having to read and think for yourself is not a strong suit for you, sorry about that.